E-submission
Search
- Page Path
- HOME > Search
Review
- A review of liver fibrosis and cirrhosis regression
- Michael J. Lee
- J Pathol Transl Med. 2023;57(4):189-195. Published online June 20, 2023
- DOI: https://doi.org/10.4132/jptm.2023.05.24
- 11,368 View
- 628 Download
- 12 Web of Science
- 15 Crossref
-
Abstract
PDF - Cirrhosis has traditionally been considered an irreversible process of end-stage liver disease. With new treatments for chronic liver disease, there is regression of fibrosis and cirrhosis, improvement in clinical parameters (i.e. liver function and hemodynamic markers, hepatic venous pressure gradient), and survival rates, demonstrating that fibrosis and fibrolysis are a dynamic process moving in two directions. Microscopically, hepatocytes push into thinning fibrous septa with eventual perforation leaving behind delicate periportal spikes in the portal tracts and loss of portal veins. Obliterated portal veins during progressive fibrosis and cirrhosis due to parenchymal extinction, vascular remodeling and thrombosis often leave behind a bile duct and hepatic artery within the portal tract. Traditional staging classification systems focused on a linear, progressive process; however, the Beijing classification system incorporates both the bidirectional nature for the progression and regression of fibrosis. However, even with regression, vascular lesions/remodeling, parenchymal extinction and a cumulative mutational burden place patients at an increased risk for developing hepatocellular carcinoma and should continue to undergo active clinical surveillance. It is more appropriate to consider cirrhosis as another stage in the evolution of chronic liver disease as a bidirectional process rather than an end-stage, irreversible state.
-
Citations
Citations to this article as recorded by
- Low-Grade Chronic Inflammation: a Shared Mechanism for Chronic Diseases
Mariana Cifuentes, Hugo E. Verdejo, Pablo F. Castro, Alejandro H. Corvalan, Catterina Ferreccio, Andrew F. G. Quest, Marcelo J. Kogan, Sergio Lavandero
Physiology.2025; 40(1): 4. CrossRef - Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
Melchor Alpízar Salazar, Samantha Estefanía Olguín Reyes, Andrea Medina Estévez, Julieta Alejandra Saturno Lobos, Jesús Manuel De Aldecoa Castillo, Juan Carlos Carrera Aguas, Samary Alaniz Monreal, José Antonio Navarro Rodríguez, Dulce María Fernanda Alpí
Medicina.2025; 61(1): 88. CrossRef - Unveiling the Link between Albumin-Bilirubin Grade and Liver Fibrosis in Patients with a History of Gallstone and Gallbladder Surgery: A Focus on Metabolic Dysfunction-Associated Steatohepatitis
Mohammadjavad Sotoudeheian
The Korean Journal of Pancreas and Biliary Tract.2025; 30(1): 10. CrossRef - Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis
Marina W. Takawy, Manal F. Abdelmalek
Current Diabetes Reports.2025;[Epub] CrossRef - Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights
Sathiyamoorthy Padmanaban, Ji-Won Baek, Sai Sahithya Chamarthy, Saipriya Chandrasekaran, Antony V. Samrot, Vijayakumar Gosu, In-Kyu Park, Kamalakannan Radhakrishnan, Don-Kyu Kim
Liver Research.2025;[Epub] CrossRef - Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes
Ashok Kumar Sah, Mohd Afzal, Rabab H. Elshaikh, Anass M. Abbas, Manar G. Shalabi, Pranav Kumar Prabhakar, Asaad M. A. Babker, Fariza Tursunbaevna Khalimova, Velilyaeva Aliya Sabrievna, Ranjay Kumar Choudhary
Life.2025; 15(5): 779. CrossRef - Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis
Tamer A. Addissouky, Majeed M. A. Ali, Ibrahim El Tantawy El Sayed, Yuliang Wang
The Egyptian Journal of Internal Medicine.2024;[Epub] CrossRef - Inhibition of hepatic stellate cell activation by nutraceuticals: an emphasis on mechanisms of action
Vasudevan Sekar, Venkateish VP, Vani Vijay, Annapoorna BR, Nivya Vijayan, Madan Kumar Perumal
Journal of Food Science and Technology.2024; 61(11): 2046. CrossRef - The Role of Macrophage Inhibitory Factor in TAA-Induced Liver Fibrosis in Mice: Modulatory Effects of Betaine
Tatjana Radosavljevic, Dusan Vukicevic, Jasmina Djuretić, Kristina Gopcevic, Milica Labudovic Borovic, Sanja Stankovic, Janko Samardzic, Milica Radosavljevic, Danijela Vucevic, Vladimir Jakovljevic
Biomedicines.2024; 12(6): 1337. CrossRef - Fibrosis and Hepatocarcinogenesis: Role of Gene-Environment Interactions in Liver Disease Progression
Anindita Banerjee, Patrizia Farci
International Journal of Molecular Sciences.2024; 25(16): 8641. CrossRef - Multiomic predictors for regression of cirrhosis: Clinical implications and future directions
Binghua Li, Decai Yu
iLIVER.2024; 3(4): 100116. CrossRef - Commonly encountered symptoms and their management in patients with cirrhosis
Cyriac Abby Philips
Frontiers in Medicine.2024;[Epub] CrossRef - Antioxidant Potential of Xanthohumol in Disease Prevention: Evidence from Human and Animal Studies
Jakub Piekara, Dorota Piasecka-Kwiatkowska
Antioxidants.2024; 13(12): 1559. CrossRef - AdhMMP8 Vector Administration in Muscle: An Alternate Strategy to Regress Hepatic Fibrosis
Jesús García-Bañuelos, Edén Oceguera-Contreras, Ana Sandoval-Rodríguez, Blanca Estela Bastidas-Ramírez, Silvia Lucano-Landeros, Daniela Gordillo-Bastidas, Belinda C. Gómez-Meda, Arturo Santos, Eira Cerda-Reyes, Juan Armendariz-Borunda
Cells.2023; 12(17): 2127. CrossRef - Nutritional deficiency in patients with liver cirrhosis
Maria S. Zhigalova, Vladimir V. Kiselev, Alla A. Ryk, Petr A. Yartsev
Clinical nutrition and metabolism.2023; 4(4): 265. CrossRef
- Low-Grade Chronic Inflammation: a Shared Mechanism for Chronic Diseases
First
Prev
